Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
BRETHINE |
| Manufacturer |
|
Xanodyne Pharmacal, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
β2-agonist. |
| Generic Name |
|
Terbutaline sulfate 2.5mg, 5mg; scored tabs. |
| Also |
|
• BRETHINE INJECTION
|
| Indications |
|
Asthma. Chronic bronchitis. Emphysema. |
| Children |
|
Not recommended. |
| Adults |
|
12–15yrs: 2.5mg 3 times daily at 6 hour intervals. >15yrs: 2.5-5mg 3 times daily at 6 hour intervals. |
| Precautions |
|
Not for management of preterm labor. Avoid excessive use. Diabetes. Cardiac disease. Hypertension. Hyperthyroidism. Seizure disorders. If subject to hypokalemia, monitor potassium. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Avoid other sympathomimetics (except aerosol bronchodilators), MAOIs, tricyclics. Antagonized by β-blockers. |
| Adverse Reactions |
|
Tachycardia, palpitations, nervousness, tremor, headache, drowsiness, nausea. |
| How Supplied |
Tabs—100, 1000
Amps (2mL)—10, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
